CLDI

1.25% -0.0018

Dopo l'orario di chiusura: .14 -0.0021 -1.48%

Calidi Biotherapeutics Inc (CLDI)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Calidi Biotherapeutics Inc

Healthcare (1094)

Biotechnology (614)

(858) 794-9600

4475 Executive Drive, Suite 200, San Diego

Prossima data di guadagno

Ultimi documenti SEC

CLDI's Discussions on Twitter

Compare CLDI vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CLDI Calidi Biotherapeutics Inc	0.1421	2.78M	0	-25.09M	-18.40M	-5.1824
VRTX Vertex Pharmaceuticals Inc	498.43	132.55B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	662.88	70.90B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	915.30	57.21B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	323.50	42.94B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.77	40.49B	742.00K	-1.37B	-1.07B	-7.0731

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-11-22	Iniziato	H.C. Wainwright	Buy
2023-10-09	Iniziato	Robert W. Baird	Outperform

Calidi Biotherapeutics Inc Borsa (CLDI) Ultime notizie

Calidi Biotherapeutics Inc Azioni (CLDI) Dati Finanziari

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Compare CLDI vs VRTX, REGN, ARGX, ALNY, RVMD

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Calidi Biotherapeutics Inc Borsa (CLDI) Ultime notizie

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times

Calidi lures new finance chief with 100,000 stock options - Stock Titan

Calidi Biotherapeutics (CLDI) stock plunges 35% after hours — here's why - MSN

CLDI Q4 2025 Earnings: Surprise EPS Beat Signals Cost Discipline Amid Pre-Revenue PhaseTech Earnings Analysis - dars.gov.et

CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Growth Report - dars.gov.et

Calidi Biotherapeutics (CLDI) director Sanders Corazon files initial Form 3 - Stock Titan

CLDI Q4 2025 Earnings: Narrower-than-expected loss boosts shares by 8.88%Low Growth Earnings - dars.gov.et

Calidi Biotherapeutics, Inc. Actuals & Estimates (AMEX:CLDI) - TradingView

Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit - Sahm

Calidi’s tumor-targeted T-cell approach aims at hard-to-hit solid tumors - Stock Titan

Form 8K Calidi Biotherapeutics Inc For: 23 June By Investing.com - Investing.com Australia

Form 8K Calidi Biotherapeutics Inc For: 23 June - Investing.com UK

Calidi Biotherapeutics Expands Board With New Independent Director - TipRanks

Calidi Biotherapeutics Appoints Industry Veteran Corsee Sanders, Ph.D., to Board of Directors to Advance RedTail Platform and CLD-401 Clinical Development – Minichart - Minichart

Calidi Biotherapeutics appoints Corsee Sanders to board - Investing.com

Industry veteran Corsee Sanders joins Calidi Biotherapeutics (CLDI) board and Audit Committee - Stock Titan

Calidi Biotherapeutics appoints Corsee Sanders to board By Investing.com - Investing.com UK

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - The Manila Times

Press Release: Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - Moomoo

Calidi adds former Genentech and Roche executive to board - Stock Titan

Calidi Biotherapeutics Inc (CLDI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Calidi Biotherapeutics (CLDI) Surges 11%: Micro-Cap Biotech Tests Key Resistance at $0.18High Yield Stocks - dars.gov.et

Calidi Biotherapeutics, Inc. Files Form 8-K with SEC: Key Corporate Details, Stock Info & NYSE American Listing - Minichart

CLDI News | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill

Calidi Biotherapeutics Stockholders Approve Key Governance Measures - TipRanks

Calidi Biotherapeutics (CLDI) stockholders back all proposals at 2026 annual meeting - Stock Titan

Calidi Biotherapeutics Inc (CLDI) Valuation: PE, PB & Fair Value Analysis - TradingKey

Calidi Biotherapeutics Inc (CLDI) Institutional Confidence - TradingKey

Calidi Biotherapeutics Inc (CLDI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Calidi Biotherapeutics Inc (CLDI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Calidi Biotherapeutics Inc (CLDI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Calidi Biotherapeutics Inc (CLDI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Calidi Biotherapeutics Inc (CLDI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Calidi Biotherapeutics Inc (CLDI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Calidi receives pre-IND feedback from FDA on CLD-401 - BioWorld News

Calidi Biotherapeutics Receives Positive Feedback From FDA for CLD-401 Pre-IND Application - marketscreener.com

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study - GlobeNewswire

CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Chart - ChartMill

CLDI Q4 2025 Earnings: Narrower Loss Signals Progress in Clinical PipelineProfit Inflection Point - newsline.com

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9 - ACCESS Newswire

Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026 - GlobeNewswire

Calidi to outline virus-based oncology platform RedTail in June 9 webinar - Stock Titan

Calidi Biotherapeutics (CLDI) Edges Lower, Testing Key Support at $0.16Regression Channel - newsline.com

CLDI Q4 2025 Earnings: Significant EPS Beat Highlights Progress in Oncolytic Virus Therapy DevelopmentFull Year Guidance - newsline.com

Calidi Biotherapeutics (CLDI) Hovers Near Key Support Amid Continued Selling PressureShakeout Pattern - newsline.com

CLDI Q4 2025 Earnings: Narrowing Losses Exceed Expectations Amid Continued Pipeline DevelopmentMargin Expansion Trends - dars.gov.et

Calidi Biotherapeutics, Inc. Files Form 8-K Disclosing Amended and Restated Warrant Agreement – Key Details and XBRL Data - Minichart

Calidi Biotherapeutics Amends Warrant in Private Placement - TipRanks

Calidi Biotherapeutics Amends Warrant for 17.4M Shares at $0.23; Stockholder OK Required - TradingView

Calidi (NYSE: CLDI) extends vesting and adjusts major warrant terms - Stock Titan

Number of shareholders of Calidi Biotherapeutics, Inc. – AMEX:CLDI - TradingView

Calidi Biotherapeutics Inc Azioni (CLDI) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a CLDI